Abstracts Archive - Page 2336 of 2425 - ACR Meeting Abstracts

Abstract Number: 1280 • 2012 ACR/ARHP Annual Meeting
Sustained Efficacy Responses and a Consistent Safety Profile with Rituximab Repeat Treatment Over 5 Years in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumour Necrosis Factor Inhibitors
Edward Keystone¹, Stanley B. Cohen², Paul Emery³, Joel M. Kremer⁴, Maxime R. Dougados⁵, James E. Loveless⁶, Carol Chung⁷, Pamela Wong⁷, Patrica B. Lehane⁸ and Helen Tyrrell⁸, ¹The Rebecca MacDonald Centre for Arthritis and Autoimmunity, Mount Sinai Hospital, Toronto, ON, Canada, ²Metroplex Clinical Research Center, Dallas, TX, ³Division of Rheumatic & Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ⁴Center for Rheumatology, Albany Medical College, Albany, NY, ⁵Hopital Cochin, René Descartes University, Paris, France, ⁶St Luke's Rheumatology, Boise, ID, ⁷Genentech, Inc., South San Francisco, CA, ⁸Roche Products Limited, Welwyn Garden City, United Kingdom
Background/Purpose: In the REFLEX study conducted in anti-TNF inadequate responder (TNF-IR) patients with RA, a single course of rituximab (RTX) in combination with methotrexate (MTX)…
Abstract Number: 1281 • 2012 ACR/ARHP Annual Meeting
IL-6 Signaling Inhibition Improves Abnormal Bone Homeostasis in Active Rheumatoid Arthritis
Masayasu Kitano¹, Sachie Kitano¹, Chieri Sato¹, Kazuyuki Fujita¹, Takahiro Yoshikawa¹, Yuki Katashima¹, Masahiro Sekiguchi¹, Naoto Azuma¹, Naoaki Hashimoto, Shinichiro Tsunoda¹, Kiyoshi Matsui¹ and Hajime Sano¹, ¹Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya-city, Japan
Background/Purpose: Tocilizumab (TCZ) is a humanized monoclonal anti-IL-6 receptor antibody. TCZ has demonstrated efficacy in moderate to severe active rheumatoid arthritis (RA) with inadequate clinical…
Abstract Number: 1282 • 2012 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy up to 48 Months
Jurgen Wollenhaupt¹, Joel C. Silverfield², Eun Bong Lee³, Susan P. Wood⁴, Koshika Soma⁵, Lisy Wang⁴, Hiroyuki Nakamura⁶, Yoshihiro Komuro⁶, Chudi I. Nduaka⁴, David Gruben⁴, Birgitta Benda⁷, Samuel H. Zwillich⁵, Richard Riese⁴ and John D. Bradley⁴, ¹Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ²Healthpoint Medical Group, Tampa, FL, ³Seoul National University, Seoul, South Korea, ⁴Pfizer Inc., Groton, CT, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Japan Inc., Tokyo, Japan, ⁷Pfizer Inc., Collegeville, PA
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy in RA. Here we report the safety…
Abstract Number: 1283 • 2012 ACR/ARHP Annual Meeting
Effects of Tofacitinib On Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis Receiving Stable-Dose Methotrexate: Results of Two Phase 3 Studies
Gerd Burmester¹, Désirée van der Heijde², Vibeke Strand³, Cristiano A. F. Zerbini⁴, Carol A. Connell⁵, Charles A. Mebus⁵, Samuel H. Zwillich⁶, John D. Bradley⁵, David Gruben⁵ and Gene Wallenstein⁵, ¹Department of Rheumatology and Clinical Immunology, Charité – University Medicine Berlin, Berlin, Germany, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ⁴Centro Paulista de Investigação Clinica, Sao Paulo, Brazil, ⁵Pfizer Inc., Groton, CT, ⁶Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. The efficacy and safety of…
Abstract Number: 1284 • 2012 ACR/ARHP Annual Meeting
Evaluation of Influenza and Pneumococcal Vaccine Responses in Patients with Rheumatoid Arthritis Receiving Tofacitinib
K. L. Winthrop¹, A. Racewicz², E. B. Lee³, B. Wilkinson⁴, S. H. Zwillich⁵, K. Soma⁴, S. Rottinghaus⁴, T. Kawabata⁴, R. Riese⁵, S. Wood⁵, J. Bradley⁶ and Clifton O. Bingham III⁷, ¹Division of Infectious Diseases, Oregon Health and Science University, Portland, OR, ²Department of Internal Medicine and Osteoarthrology, Bialystok Regional Hospital, Bialystok, Poland, ³Seoul National University, Seoul, South Korea, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc., Groton, CT, ⁶Worldwide Pharmaceutical Development, Pfizer Inc., Groton, CT, ⁷Rheumatology, Johns Hopkins University, Baltimore, MD
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. Clinical guidelines recommend the use…
Abstract Number: 1285 • 2012 ACR/ARHP Annual Meeting
Short-Term Efficacy of Etanercept Plus Methotrexate Vs.Various Disease-Modifying Anti-Rheumatic Combinations with Methotrexate in Established Rheumatoid Arthritis
Roy Fleischmann¹, Andrew S. Koenig², Annette Szumski³, Henk Nab⁴, Lisa Marshall⁵ and Eustratios Bananis³, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Specialty Care Business Unit, Pfizer Inc., Collegeville, PA, ³Specialty Care, Pfizer Inc., Collegeville, PA, ⁴Pfizer Europe, Rome, Italy, ⁵Pfizer Inc., Collegeville, PA
Background/Purpose: The objective of this study was to assess the short-term benefit of etanercept (ETN) + methotrexate (MTX) vs. various disease-modifying anti-rheumatic drugs (DMARDs; hydroxychloroquine…
Abstract Number: 1286 • 2012 ACR/ARHP Annual Meeting
Antibodies to Etanercept and Adalimumab in Rheumatoid Arthritis Inadequate Responders and Clinical Outcomes After an Active Switch to Infliximab
Chad Pool¹, Gopi Shankar², Allen Schantz², George Gunn², Rebecca Bolce³, Marjatta Leirisalo-Repo⁴, Jim Wang¹, John A. Goldman⁵, Raphael J. DeHoratius⁶, Roy Fleischmann⁷ and Dennis Decktor⁶, ¹Janssen Services, LLC, Horsham, PA, ²Janssen R&D, LLC, PA, ³Crescendo Bioscience Inc., South San Francisco, CA, ⁴Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Helsinki, Finland, ⁵Medical Quarters #293, Atlanta, GA, ⁶Medical Affairs, Janssen Services, LLC, Horsham, PA, ⁷Rheumatology, University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: To determine if RA patients (pts) who had an inadequate response to etanercept(ETN) or adalimumab(ADA) and developed antibodies (Abs) to ETN or ADA responded…
Abstract Number: 1287 • 2012 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Comparison of Active Therapies in Methotrexate Suboptimal Responders: Validation of the Strategy of Conventional Disease Modifying Anti-Rheumatic Drugs Before Biologicals
James R. O'Dell¹, Ted R. Mikuls², Thomas Taylor³, Vandana Ahluwalia⁴, Mary Brophy⁵, Stuart Warren⁶, Robert Lew⁵, Ciaran Phibbs⁷, Aslam H. Anis⁸, Amy C. Cannella⁹, Gary A. Kunkel¹⁰, Alan R. Erickson², Edward Keystone¹¹ and the CSP551 RACAT Research Group¹², ¹Dept of Internal Medicine, Omaha VA and University of Nebraska Medical Center, Omaha, NE, ²Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ³VA Medical Center, White River Junction, VT, ⁴William Osler Health Center, Brampton, ON, Canada, ⁵VA Boston Heathcare System, Boston, MA, ⁶VA CSP Clinical Research Pharmacy Coordinating Center, Albuquerque, NM, ⁷Health Economics Resource Center (152), Palo Alto VA Health Care System, Menlo Park, CA, ⁸Population and Public Health, Univ of British Columbia, Vancouver, BC, Canada, ⁹Divison of Rheumatology, Omaha VA and University of Nebraska Medical Center, Omaha, NE, ¹⁰Div of Rheumatology, George Wahlen Veterans Affairs Medical Center, Salt Lake City, UT, ¹¹University of Toronto, Toronto, ON, Canada, ¹²Boston, MA
Background/Purpose: Double-blind placebo controlled randomized trials have demonstrated the efficacy of 15 different therapies in RA patients with active disease despite methotrexate (MTX). No blinded…
Abstract Number: 1288 • 2012 ACR/ARHP Annual Meeting
A Significant Number of Patients with Chronic Arthritis Received a Reduced Dosage of Biological Drugs: an Observational Study in Clinical Practice
Jose Inciarte-Mundo¹, Maria Victoria Hernández², Violeta Rosario¹, Sonia Cabrera¹, Virginia Ruiz-Esquide³, Maria Eugenia Gomez-Caballero¹, Jose A. Gómez-Puerta¹, Julio Ramirez¹, Juan D. Cañete² and Raimon Sanmarti¹, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Rheumatology, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain, ³Rheumatology, Hospital Clinic, Barcelona, Spain
Background/Purpose: Biological agents are used to treat chronic arthritis according to the standard dosages from phase III clinical trials. However, in some patients, a good…
Abstract Number: 1289 • 2012 ACR/ARHP Annual Meeting
Abatacept Biologic-Free Remission Study in Established Rheumatoid Arthritis Patients. Orion Study
Tsutomu Takeuchi¹, Tsukasa Matsubara², Shuji Ohta³, Masaya Mukai⁴, Koichi Amano⁵, Shigeto Tohma⁶, Yoshiya Tanaka⁷, Hisashi Yamanaka⁸ and Nobuyuki Miyasaka⁹, ¹Keio University School of Medicine, Tokyo, Japan, ²Matsubara Mayflower Hospital, Hyogo, Japan, ³Department of Rheumatology, Taga General Hospital, Ibaraki, Japan, ⁴Dept Rheumatology & Hematology, Sapporo City General Hospital, Sapporo, Japan, ⁵Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, ⁶Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, ⁷The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁸Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁹Department of Medicine and Rheumatology and Global Center of Excellence Program, Tokyo Medical and Dental University, Tokyo, Japan
Background/Purpose: Abatacept (ABA) has comparable efficacy to TNF inhibitors in achieving clinical remission in rheumatoid arthritis (RA) patients. However, although clinical evidence suggests that biologic-free…
Abstract Number: 1290 • 2012 ACR/ARHP Annual Meeting
Effects of Tofacitinib On Lipid Profiles and Cholesterol and Lipoprotein Kinetics in Patients with Rheumatoid Arthritis
Christina Charles-Schoeman¹, Roy Fleischmann², Jean Davignon³, Howard Schwartz⁴, Scott Turner⁵, Carine Beysen⁵, Mark Milad⁶, Zheng Luo⁷, John Bradley⁸, Irina Kaplan⁸, Richard Riese⁷, Andrea Zuckerman⁷ and Iain B. McInnes⁹, ¹University of California, Los Angeles, CA, ²Metroplex Clinical Research Center, Dallas, TX, ³University of Montreal, Montreal, Canada, ⁴Miami Research Associates, Miami, FL, ⁵KineMed Inc., Emeryville, CA, ⁶Milad Pharmaceutical Consulting LLC, Plymouth, MI, ⁷Pfizer Inc., Groton, CT, ⁸Pfizer Inc, Groton, CT, ⁹Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Tofacitinib is a novel oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. In RA patients (pts), suppression…
Abstract Number: 1291 • 2012 ACR/ARHP Annual Meeting
A Phase Ib Clinical Trial with F8-IL10, an Anti-Inflammatory Immunocytokine for the Treatment of Rheumatoid Arthritis (RA), Used in Combination with Methotrexate (MTX)
Mauro Galeazzi¹, Caterina Baldi¹, Elena Prisco², Marco Bardelli¹, Dario Neri³, Leonardo Giovannoni⁴, Enrico Selvi¹ and Roberto Caporali², ¹Rheumatology, University of Siena, Siena, Italy, ²Rheumatology, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, ³Chemistry and Applied Biosciences, Swiss Federal Institute of Technology Zurich, Zurich, Switzerland, ⁴Philogen S.p.A., Siena, Italy
Background/Purpose: Interleukin 10 (IL10) is an anti-inflammatory cytokine potentially efficacious for RA. F8-IL10 is a fusion protein in which the cytokine is fused with the…
Abstract Number: 1292 • 2012 ACR/ARHP Annual Meeting
Fatigue Is an Independent Variable Predicting Physical Function and Disease Activity Score-28 Remission for Patients with Rheumatoid Arthritis Treated with Intravenously Administered Golimumab: Results From Phase 3, Placebo Controlled Clinical Trial
Rene Westhovens¹, Michael Weinblatt², Chenglong Han³, Tim Gathany⁴, Lilianne Kim⁵, Michael Mack⁶, Jiandong Lu⁶, Daniel Baker⁷, Alan Mendelsohn⁷ and Clifton O. Bingham III⁸, ¹Rheumatology, University Hospital KU Leuven, Leuven, Belgium, ²Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ³Outcomes Research, Johnson & Johnson Pharmaceutical Services, LLC, Malvern, PA, ⁴Janssen Global Services, LLC., Malvern, PA, ⁵Janssen Research & Development, a division of Pharmaceutical Research & Development LLC, Janssen Research & Development, LLC, Malvern, PA, ⁶Biostatistics, Janssen Research & Development, LLC., Spring House, PA, ⁷Immunology, Janssen Research & Development, LLC, Spring House, PA, ⁸Department of Medicine, Johns Hopkins University, Baltimore, MD
Background/Purpose: To evaluate the association of fatigue with physical function and disease activity in patients with rheumatoid arthritis (RA), and the impact of treatment with…
Abstract Number: 1293 • 2012 ACR/ARHP Annual Meeting
Importance of Steady-State Trough Concentrations After Intravenous Golimumab with Concomitant Methotrexate in Subjects with Active Rheumatoid Arthritis
J. H. Leu¹, Z. Xu¹, C. Hu¹, Alan Mendelsohn¹, J. Ford¹, Hugh M. Davis² and H. Zhou¹, ¹Janssen Research and Development, LLC, Spring House, PA, ²Janssen Research & Development, LLC., Spring House, PA
Background/Purpose: To determine an optimized dosing regimen for IV golimumab in subjects with active RA using population pharmacokinetic (PK) modeling and simulation. Methods: Two Phase…
Abstract Number: 1294 • 2012 ACR/ARHP Annual Meeting
A Phase Ib Multiple Ascending Dose Study Evaluating Safety, Pharmacokinetics, and Early Clinical Response of Brodalumab (AMG 827), a Human Anti-Interleukin 17 Receptor (IL-17R) Antibody, in Rheumatoid Arthritis
Melvin A. Churchill¹, Luis F. Flores-Suarez², Daniel J. Wallace³, Kristine Phillips⁴, Richard W. Martin⁵, Mario H. Cardiel⁶, Jeffrey Kaine⁷, Edgar Bautista⁸, David H. Salinger⁹, Erin Stevens⁹, Christopher B. Russell⁹ and David A. Martin⁹, ¹Arthritis Center of Nebraska, Lincoln, NE, ²Primary Systemic Vasculitides Clinic, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Rheumatology, University of Michigan Medical School, Ann Arbor, MI, ⁵Medicine, Rheumatology, Michigan State University College of Human Medicine, Grand Rapids, MI, ⁶Research Unit, Hospital, Morelia, Mexico, ⁷Sarasota Arthritis Research Center, Sarasota, FL, ⁸Medical Sciences, Amgen, Thousand Oaks, CA, ⁹Medical Sciences, Amgen, Seattle, WA
Background/Purpose: The cytokine IL-17A is an innate inflammatory cytokine implicated in the pathogenesis of several human autoimmune diseases including rheumatoid arthritis (RA). Brodalumab is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].